DoximityDOCS -4.62%82 3-Year EBITDA Growth Rate is 22.00% as of Mar. 2026, which is 46% below its 10-year median of 40.40. GuruFocus rates DOCS with a GF Score™ of 82/100 and a GF Value™ of $49.24 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 529 Healthcare Providers & Services companies, Doximity ranks better than 68.24% on this metric.
During the past 12 months, Doximity's average EBITDA Per Share Growth Rate was -3.80% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 22.00% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 28.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 8 years, the highest 3-Year average EBITDA Per Share Growth Rate of Doximity was 141.70% per year. The lowest was 22.00% per year. And the median was 40.40% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Doximity 3-Year EBITDA Growth Rate Related Terms
DOCS vs WAY, PRVA, HTFL: 3-Year EBITDA Growth Rate Comparison
For the Health Information Services subindustry, Doximity's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Doximity 3-Year EBITDA Growth Rate vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Doximity's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Doximity's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 22.00% mean?
Doximity (DOCS) has a 3-Year EBITDA Growth Rate of 22.00% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Doximity and its competitors. This is 46% below median its historical median of 40.40. Over the past decade, Doximity's 3-Year EBITDA Growth Rate has ranged from 22.00 to 141.70. According to the industry distribution chart, Doximity ranks #168 out of 529 companies in the Healthcare Providers & Services industry, placing it in the top 31.8%.
Is Doximity's 3-Year EBITDA Growth Rate too high?
Doximity's current 3-Year EBITDA Growth Rate of 22.00% is 46% below median its 10-year median of 40.40. Over the past 10 years, this metric has ranged from a low of 22.00 to a high of 141.70. The Healthcare Providers & Services industry median 3-Year EBITDA Growth Rate is 10.20. Doximity's value of 22.00% is 115.7% above this industry median. Based on the distribution chart, Doximity ranks #168 out of 529 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Doximity has a GF Score™ of 82/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Doximity's 3-Year EBITDA Growth Rate compare to WAY and PRVA?
According to the Healthcare Providers & Services industry distribution chart, Doximity ranks #168 out of 529 companies for 3-Year EBITDA Growth Rate. This puts Doximity in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 10.20. Doximity's value of 22.00% is 115.7% above this benchmark. Historically, Doximity's own 3-Year EBITDA Growth Rate has ranged from 22.00 to 141.70 over the past decade. While the company's 10-year median is 40.40 vs. the industry median of 10.20, Doximity has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Healthcare Providers & Services company?
The median 3-Year EBITDA Growth Rate among Healthcare Providers & Services companies is 10.20, based on 529 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Doximity's current 3-Year EBITDA Growth Rate of 22.00% is 115.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Doximity and its competitors. For the Healthcare Providers & Services industry, the median 3-Year EBITDA Growth Rate is 10.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Doximity's current 3-Year EBITDA Growth Rate is 22.00%, which is 46% below median its own 10-year median of 40.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Doximity stock overvalued right now?
Based on GuruFocus' analysis, Doximity (DOCS) is currently considered Significantly Undervalued. The stock's GF Value™ is $49.24, compared to a current price of $21.69 — trading 56% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 22.00%, which is 46% below median its 10-year median of 40.40 and 115.7% above the Healthcare Providers & Services industry median of 10.20. Doximity's overall GF Score™ is 82/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Doximity (DOCS), the current 3-Year EBITDA Growth Rate is 22.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Doximity (DOCS) Overvalued in 2026?
Based on GuruFocus' analysis, Doximity stock appears to be undervalued.
The current stock price of $21.69 is trading 56% below its estimated GF Value™ of $49.24.
GuruFocus considers Doximity to be Significantly Undervalued.
Key valuation signals for DOCS:
3-Year EBITDA Growth Rate: 22.00% (46% below median its 10-year median of 40.40)
GF Value™: $49.24 vs. price of $21.69 (56% below fair value)
Industry Position: 115.7% above the Healthcare Providers & Services median (#168 of 529)
No single metric tells the full story. See the DOCS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Doximity Inc provides an online platform, which enables physicians and other healthcare professionals to collaborate with colleagues, stay up to date with the latest medical news and research, manage their careers and on-call schedules, streamline documentation and administrative paperwork, and conduct virtual patient visits. The Company's customers include pharmaceutical companies and health systems that connect with healthcare professionals through the Company's digital Marketing, Hiring, and Workflow Solutions. Marketing Solutions provide customers with the ability to share tailored content on the network. Hiring Solutions enable customers to identify, connect with, and hire from the network of both active and passive potential medical professional candidates.
82GF Score
Get the complete analysis for DOCS
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DOCS has been successfully added to your 